NapaJen Pharma, Inc.
NapaJen Pharma, Inc. 533 Airport Blvd.,#527, Burlingame, CA 94010 USA CEO Kenji Arima
Board of Directors
CEO: Kenji Arima CFO, Secretary： Takuma Nakatsuka Director： Kenji Arima Director： Koichi Ashida Director： Kinji Fuchikami Director： Maya Fujita
Kenji Arima, Chief Executive Officer
Dr. Arima joined NapaJen as chief development officer in 2016 and was appointed to the role of chief executive officer in 2019. A 40-year veteran of the pharmaceutical industry, he possesses a track record of leadership roles including translational research through clinical trials, as well as licensing and intellectual asset management. Most recently, at AMED (Japan Agency for Medical Research and Development), Dr. Arima played a key role in establishing the Drug-discovery Innovation and Screening Consortium, which produced unique chemical libraries of 200,000 compounds from more than 20 pharmaceutical companies. Prior to joining AMED, he was president of Asubio Pharmaceuticals, Inc. in the US from 1999 to 2010, where he successfully led multiple development programs in the US, EU and other countries. From 2007 to 2010, he served as director and president of New York Pharma Forum. He holds a Ph.D. degree from Kyoto University.
Takuma Nakatsuka, Chief Financial Officer
Mr. Nakatsuka joined Napajen as chief financial officer (CFO) in 2019.He has previously served as CFO and/or chief executive officer for a number of companies spanning both the life science and engineering fields. In the life science/biopharma industry, Mr. Nakatsuka has held management positions with AnGes MG, Nanocarrier, Genomidia, Quantum Biosystems and Schering Japan. Additionally, he has served in management roles for leading engineering companies such as Hosokawa Micron, Veolia-Water Japan, Nishihara Environmental Technology and Nishihara Techno Service. Prior to these management roles, Mr. Nakatsuka spent 14 years serving the National Government of Japan, holding positions within the Department of Prime Minister and Cabinet, Office of Public Management and Coordination and Ministry of Foreign Affairs. He received a law degree from the University of Tokyo, a Master’s degree from the University of Michigan in economics and public policy, and an MBA from the Wharton School, University of Pennsylvania.
Kazuaki Sakurai, Chief Scientific Officer
An eminent figure in the field of polymer science, Dr. Sakurai is the scientific co-founder of NapaJen and the principle inventor of the company’s novel immune cell-targeted oligonucleotide delivery technology. He also serves as a professor in the department of chemistry and biochemistry at the University of Kitakyushu, where he continues his discovery contributions. His major research interests include polysaccharides, polysaccharide-polynucleotide complexes, nucleic acid delivery, and small-angle X-ray scatter analyses. As part of the Japanese National Chemo-transfiguration Research Project, his broad contributions gave birth to a new national project entitled “Sugar-Based Gene Manipulators.” Earlier in his career he spent 16 years at the central research center of Kanebo Ltd., performing research that spanned conductive polymers, optical resins, and drug delivering systems. Prior to that he was honored with a scholarship for his work in the department of polymer science at the University of Massachusetts, where he spent three years as a visiting scholar. He received his Ph.D. degree from Osaka University.
NapaJen Pharma Co., Ltd. Tama-Koganei Venture Port 302, 2-24-16 Nakacho, Koganei, Tokyo 184-0012 Japan
NapaJen Pharma Co., Ltd. Officers
CEO & President: Kenji Arima
Officer: Kazuo Sakurai
Officer: Takuma Nakatsuka
Officer: Akihiko Tachiyama
Officer: Takanori Yasui
NapaJen Pharma, Inc.
Tel: 650-685-2429 FAX: 650-401-2221 email: email@example.com
NapaJen Pharma Co., Ltd.
Tel : +81-42-316-6773 Fax : +81-42-388-7757 email: firstname.lastname@example.org